Risk-benefit analysis of 18FDG PET cancer screening
Creators
- 1. National Cancer Center, Research Center for Cancer Prevention and Screening, Tokyo (Japan)
- 2. National Inst. of Radiological Sciences, Chiba, Chiba (Japan)
- 3. National Cancer Center Hospital, Tokyo (Japan)
- 4. High Energy Accelerator Research Organization, Tsukuba, Ibaraki (Japan)
- 5. Yokohama City Univ., Graduate School of Medicine, Yokohama, Kanagawa (Japan)
Description
The benefits of 18F-fluorodeoxyglucose (18FDG) positron emission tomography (PET) cancer screening are expected to include a large population of examinees and are intended for a healthy group. Therefore, we attempted to determine the benefit/risk ratio, estimated risk of radiation exposure, and benefit of cancer detection. We used software that embodied the method of the International Commission on Radiological Protection (ICRP) to calculate the average duration of life of radiation exposure. We calculated the lifesaving person years of benefit to be obtained by 18FDG PET cancer screening detection. We also calculated the benefit/risk ratio using life-shortening and lifesaving person years. According to age, the benefit/risk ratio was more than 1 at 35-39 years old for males and 30-34 years old for females. 18FDG PET cancer screening also is effective for examinees older than this. A risk-benefit analysis of 18FDG-PET/computed tomography (CT) cancer screening will be necessary in the future. (author)
Additional details
Publishing Information
- Journal Title
- Nippon Hoshasen Gijutsu Gakkai Zasshi
- Journal Volume
- 64
- Journal Issue
- 9
- Journal Page Range
- p. 1151-1156
- ISSN
- 0369-4305
INIS
- Country of Publication
- Japan
- Country of Input or Organization
- Japan
- INIS RN
- 40009010
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- BIOLOGICAL RADIATION EFFECTS; CARCINOGEN SCREENING; CARCINOMAS; FLUORINE 18; FLUORODEOXYGLUCOSE; LEUKEMIA; LIFETIME; LYMPHOMAS; MEDICAL EXAMINATIONS; PATIENTS; POSITRON COMPUTED TOMOGRAPHY; RADIATION DOSES; RISK ASSESSMENT; SENSITIVITY
- Descriptors DEC
- ANTIMETABOLITES; BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; BIOLOGICAL EFFECTS; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC TECHNIQUES; DISEASES; DOSES; DRUGS; EMISSION COMPUTED TOMOGRAPHY; FLUORINE ISOTOPES; HOURS LIVING RADIOISOTOPES; IMMUNE SYSTEM DISEASES; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LIGHT NUCLEI; MEDICAL SURVEILLANCE; NANOSECONDS LIVING RADIOISOTOPES; NEOPLASMS; NUCLEI; ODD-ODD NUCLEI; RADIATION EFFECTS; RADIOISOTOPES; TOMOGRAPHY